Tigecycline-based therapy for glycopeptideresistant Enterococcus faecium infection in a pediatric intensive care unit

##plugins.themes.academic_pro.article.sidebar##

Published Nov 29, 2016
Download
pdf
Vol. 94 No. 6 (2016): Issue Jun 2016

##plugins.themes.academic_pro.article.main##

Becem Trabelsi
Mehdi Trifa
Sonia Ben Khalifa

##plugins.themes.academic_pro.article.details##

References

  1. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470-80.
  2. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157-61.
  3. Jaspan HB, Brothers AW, Pak D, Weissman SJ. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J. 2010;29:379-81.
  4. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label,ascending-dose study. Clin Ther. 2012;34:496-507.
  5. Hurtado IC, Trujillo M, Restrepo A, Garcés C, Tamayo C, Mesa JG. Experiencia con el uso compasivo de tigeciclina en pacientes pediátricos infectados por Klebsiella pneumoniae productora de carbapenemasas. Rev Chil Infectol. 2012;29:317-21.
  6. Du X, Fu Y, Yu Y. Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient. Ann Clin Microbiol Antimicrob. 2013;12:19.
  7. Foresti S, Di Bella S, Rovelli A, et al. Tigecycline Lock Therapy for Catheter-Related Bloodstream Infection Caused by KPC-Producing Klebsiella pneumoniae in Two Pediatric Hematological Patients. Antimicrob Agents Chemother. 2015;59:7919-20.